OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

Date of occurrence of the event: January 25, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): Head office Reciprocal shareholding ratios: N/A Name of mass media: N/A Content reported: N/A Cause of occurrence: OBI-822 was approved for 2017L00106 to conduct the Phase III clinical trial by […]

This article is password protected.

To view the content, please enter your password in the field below